argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
argenx SE ADR ARGX
News
argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
argenx Down Nearly 13%, on Pace for Largest Percent Decrease Since December 2023 — Data Talk
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
argenx to Present at Upcoming Investor Conferences
argenx Completes Acquisition of Forte Biosciences, Inc.
argenx SE Up Over 15%, On Pace For Largest Percent Increase Since July 2023 — Data Talk
Argenx Shares Rise After Positive Results From Phase 3 Study of Efgartigimod
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
Forte Biosciences Shares Leap Premarket on Takeover by Argenx
Argenx to Buy Forte Biosciences for $2.2 Billion
United States